Gline Matthew, CEO of Roivant Sciences Ltd. ($ROIV), bought shares once on the open market in the last year for nearly $50,000, with the latest purchase on September 18, 2025. This ranks 3,025th among 4,983 insiders, below the average of $1.5 million across 3.29 transactions. He sold shares three times for $37.7 million total, most recently on December 15, 2025, ranking 403rd out of 11,678 insiders versus an average of $8.6 million over 6.37 transactions.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 30, 2026 | Roivant Sciences Ltd. | $ROIV | Gline Matthew | CEO | M | Capped Value Appreciation Rights | 2178150 | $11.50 | 0.0000 | 696,859,682 | 100.00% | 0.31% |
| March 30, 2026 | Roivant Sciences Ltd. | $ROIV | Gline Matthew | CEO | M | Common Shares | 97319 | $0.00 | 17,384,400.0000 | 696,859,682 | 0.56% | 0.01% |
| March 30, 2026 | Roivant Sciences Ltd. | $ROIV | Gline Matthew | CEO | F | Common Shares | 53826 | $26.41 | 17,330,574.0000 | 696,859,682 | 0.31% | 0.01% |
| March 31, 2026 | Roivant Sciences Ltd. | $ROIV | Gline Matthew | CEO | F | Common Shares | 304684 | $27.70 | 17,025,890.0000 | 696,859,682 | 1.76% | 0.04% |
| Dec. 15, 2025 | Roivant Sciences Ltd. | $ROIV | Gline Matthew | CEO | M | Common Shares | 234096 | $4.06 | 17,521,177.0000 | 680,947,866 | 1.35% | 0.03% |
| Dec. 15, 2025 | Roivant Sciences Ltd. | $ROIV | Gline Matthew | CEO | M | Common Shares | 2272852 | $12.68 | 19,559,933.0000 | 680,947,866 | 13.15% | 0.33% |
| Dec. 15, 2025 | Roivant Sciences Ltd. | $ROIV | Gline Matthew | CEO | J | Common Shares | 797595 | $21.68 | 17,287,081.0000 | 680,947,866 | 4.41% | 0.12% |
| Dec. 15, 2025 | Roivant Sciences Ltd. | $ROIV | Gline Matthew | CEO | S | Common Shares | 566116 | $21.68 | 18,084,676.0000 | 680,947,866 | 3.04% | 0.08% |
| Dec. 15, 2025 | Roivant Sciences Ltd. | $ROIV | Gline Matthew | CEO | M | Common Shares | 1363711 | $12.68 | 18,650,792.0000 | 680,947,866 | 7.89% | 0.20% |
| Dec. 15, 2025 | Roivant Sciences Ltd. | $ROIV | Gline Matthew | CEO | J | Common Shares | 3739 | $21.68 | 17,287,081.0000 | 680,947,866 | 0.02% | 0.00% |
| Dec. 15, 2025 | Roivant Sciences Ltd. | $ROIV | Gline Matthew | CEO | S | Common Shares | 230357 | $21.68 | 17,290,820.0000 | 680,947,866 | 1.31% | 0.03% |
| Dec. 15, 2025 | Roivant Sciences Ltd. | $ROIV | Gline Matthew | CEO | M | Stock Option (Right to Buy) | 2272852 | $0.00 | 0.0000 | 680,947,866 | 100.00% | 0.33% |
| Dec. 15, 2025 | Roivant Sciences Ltd. | $ROIV | Gline Matthew | CEO | M | Stock Option (Right to Buy) | 1363711 | $0.00 | 0.0000 | 680,947,866 | 100.00% | 0.20% |
| Dec. 15, 2025 | Roivant Sciences Ltd. | $ROIV | Gline Matthew | CEO | M | Stock Option (Right to Buy) | 234096 | $0.00 | 0.0000 | 680,947,866 | 100.00% | 0.03% |
| Dec. 15, 2025 | Roivant Sciences Ltd. | $ROIV | Gline Matthew | CEO | J | Common Shares | 1329325 | $21.68 | 17,287,081.0000 | 680,947,866 | 7.14% | 0.20% |
| Dec. 15, 2025 | Roivant Sciences Ltd. | $ROIV | Gline Matthew | CEO | S | Common Shares | 943527 | $21.68 | 18,616,406.0000 | 680,947,866 | 4.82% | 0.14% |
| Sept. 18, 2025 | Roivant Sciences Ltd. | $ROIV | Gline Matthew | CEO | P | Common Shares | 3315 | $15.07 | 17,287,081.0000 | 725,395,624 | 0.02% | 0.00% |
| May 20, 2025 | Roivant Sciences Ltd. | $ROIV | Gline Matthew | CEO | F | Common Shares | 10945 | $11.04 | 17,283,766.0000 | 725,395,624 | 0.06% | 0.00% |
| April 20, 2025 | Roivant Sciences Ltd. | $ROIV | Gline Matthew | CEO | F | Common Shares | 10945 | $10.15 | 17,294,711.0000 | 725,395,624 | 0.06% | 0.00% |
| March 20, 2025 | Roivant Sciences Ltd. | $ROIV | Gline Matthew | CEO | F | Common Shares | 10945 | $10.97 | 17,305,656.0000 | 731,318,202 | 0.06% | 0.00% |
| Feb. 20, 2025 | Roivant Sciences Ltd. | $ROIV | Gline Matthew | CEO | F | Common Shares | 10945 | $10.72 | 17,316,601.0000 | 731,318,202 | 0.06% | 0.00% |
| Jan. 20, 2025 | Roivant Sciences Ltd. | $ROIV | Gline Matthew | CEO | F | Common Shares | 11623 | $11.15 | 17,327,546.0000 | 731,318,202 | 0.07% | 0.00% |
| Dec. 20, 2024 | Roivant Sciences Ltd. | $ROIV | Gline Matthew | CEO | F | Common Shares | 10945 | $11.57 | 17,339,169.0000 | 735,642,721 | 0.06% | 0.00% |
| Nov. 20, 2024 | Roivant Sciences Ltd. | $ROIV | Gline Matthew | CEO | F | Common Shares | 10945 | $11.49 | 17,350,114.0000 | 735,642,721 | 0.06% | 0.00% |
| Oct. 20, 2024 | Roivant Sciences Ltd. | $ROIV | Gline Matthew | CEO | F | Common Shares | 10945 | $11.92 | 17,361,059.0000 | 735,642,721 | 0.06% | 0.00% |
| Sept. 23, 2024 | Roivant Sciences Ltd. | $ROIV | Gline Matthew | CEO | M | Common Shares | 1550000 | $3.85 | 19,853,800.0000 | 831,049,444 | 8.47% | 0.19% |
| Sept. 23, 2024 | Roivant Sciences Ltd. | $ROIV | Gline Matthew | CEO | S | Common Shares | 1983257 | $11.79 | 17,870,543.0000 | 831,049,444 | 9.99% | 0.24% |
| Sept. 23, 2024 | Roivant Sciences Ltd. | $ROIV | Gline Matthew | CEO | J | Common Shares | 498539 | $11.97 | 17,372,004.0000 | 831,049,444 | 2.79% | 0.06% |
| Sept. 23, 2024 | Roivant Sciences Ltd. | $ROIV | Gline Matthew | CEO | M | Stock Option (Right to Buy) | 1550000 | $0.00 | 14,973,184.0000 | 831,049,444 | 9.38% | 0.19% |
| Sept. 20, 2024 | Roivant Sciences Ltd. | $ROIV | Gline Matthew | CEO | F | Common Shares | 10945 | $11.97 | 18,303,800.0000 | 831,049,444 | 0.06% | 0.00% |
| Aug. 20, 2024 | Roivant Sciences Ltd. | $ROIV | Gline Matthew | CEO | F | Common Shares | 10947 | $11.48 | 18,314,745.0000 | 831,049,444 | 0.06% | 0.00% |
| July 26, 2024 | Roivant Sciences Ltd. | $ROIV | Gline Matthew | CEO | A | Common Shares | 14450000 | $0.00 | 18,325,692.0000 | 831,049,444 | 372.84% | 1.74% |
| July 26, 2024 | Roivant Sciences Ltd. | $ROIV | Gline Matthew | CEO | A | Common Shares | 2754821 | $0.00 | 3,875,692.0000 | 831,049,444 | 245.78% | 0.33% |
| July 20, 2024 | Roivant Sciences Ltd. | $ROIV | Gline Matthew | CEO | F | Common Shares | 10945 | $11.00 | 1,120,871.0000 | 831,049,444 | 0.97% | 0.00% |
| June 20, 2024 | Roivant Sciences Ltd. | $ROIV | Gline Matthew | CEO | F | Common Shares | 10945 | $10.80 | 1,131,816.0000 | 831,049,444 | 0.96% | 0.00% |
| May 20, 2024 | Roivant Sciences Ltd. | $ROIV | Gline Matthew | CEO | F | Common Shares | 10945 | $11.37 | 1,142,761.0000 | 831,049,444 | 0.95% | 0.00% |
| April 20, 2024 | Roivant Sciences Ltd. | $ROIV | Gline Matthew | CEO | F | Common Shares | 10945 | $10.46 | 1,153,706.0000 | 831,049,444 | 0.94% | 0.00% |
| March 30, 2024 | Roivant Sciences Ltd. | $ROIV | Gline Matthew | CEO | M | Common Shares | 390579 | $0.00 | 1,380,642.0000 | 712,791,115 | 39.45% | 0.05% |
| March 30, 2024 | Roivant Sciences Ltd. | $ROIV | Gline Matthew | CEO | F | Common Shares | 215991 | $10.54 | 1,164,651.0000 | 712,791,115 | 15.64% | 0.03% |
| March 30, 2024 | Roivant Sciences Ltd. | $ROIV | Gline Matthew | CEO | M | Capped Value Appreciation Rights | 994373 | $6.40 | 0.0000 | 712,791,115 | 100.00% | 0.14% |
| March 20, 2024 | Roivant Sciences Ltd. | $ROIV | Gline Matthew | CEO | F | Common Shares | 10945 | $10.01 | 990,063.0000 | 712,791,115 | 1.09% | 0.00% |
| Feb. 20, 2024 | Roivant Sciences Ltd. | $ROIV | Gline Matthew | CEO | F | Common Shares | 10945 | $11.54 | 1,001,008.0000 | 712,791,115 | 1.08% | 0.00% |
| Jan. 20, 2024 | Roivant Sciences Ltd. | $ROIV | Gline Matthew | CEO | F | Common Shares | 10945 | $10.35 | 1,011,953.0000 | 712,791,115 | 1.07% | 0.00% |